Citius Onology ISIN: US17331Y1091 Forum: Aktien User: Money25

Citius Oncology (Nasdaq: CTOR) announced a concurrent registered direct offering and private placement expected to raise approximately $18 million gross, with closings on or about December 10, 2025. The transactions include the sale of 1,284,404 shares in the registered direct and 15,229,358 shares (or pre-funded warrants) in the private placement at $1.09 per share, plus accompanying warrants exercisable upon stockholder approval and expiring five years after approval. The company said net proceeds will support the commercial launch of LYMPHIR and general corporate purposes; H.C. Wainwright is sole placement agent. The company also agreed to amend existing warrants covering 11,961,040 shares to a reduced exercise price of $1.09, effective on closing.